Details for Patent: 7,994,214

Which drugs does patent 7,994,214 protect, and when does it expire?

Patent 7,994,214 protects ENVARSUS XR and is included in one NDA.

This patent has thirty-six patent family members in sixteen countries.

Summary for Patent: 7,994,214

Title:	Solid dispersions comprising tacrolimus
Abstract:	A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
Inventor(s):	Holm; Per (Vanlose, DK)
Assignee:	Lifecycle Pharma A/S (Horsholm, DK)
Application Number:	10/569,863
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 7,994,214

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-001	Jul 10, 2015		RX	Yes	No			Y
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-002	Jul 10, 2015		RX	Yes	No			Y
Veloxis Pharms Inc	ENVARSUS XR	tacrolimus	TABLET, EXTENDED RELEASE;ORAL	206406-003	Jul 10, 2015		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 7,994,214

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2003 01232	Aug 29, 2003
Denmark	2003 01837	Dec 11, 2003
Denmark	2004 00079	Jan 21, 2004

PCT Information
PCT Filed	August 30, 2004	PCT Application Number:	PCT/DK2004/000574
PCT Publication Date:	March 10, 2005	PCT Publication Number:	WO2005/020994

International Family Members for US Patent 7,994,214

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	473003
Austria	531368
Australia	2004267909